Oric Pharmaceuticals
Présence
Oric Pharmaceuticals fait partie des...
Oric Pharmaceuticals est une société cotée sous le symbole boursier ORIC (US).
Acquisition, funding and merger involving Oric Pharmaceuticals.
- Oric Pharmaceuticals vient d'annoncer une levée de fonds de 85 millions de dollars. (publié le 28 juin 2023).
Dirigeants
Voir l'organigramme avec ses 13 principaux dirigeants
Biographies les plus recherchées chez Oric Pharmaceuticals
- Jacob Chacko, Chief Executive Officer and Director
- Mardi Dier, Director
- Richard Heyman, Chairman of the Board
Créer une alerte
pour suivre les mouvements de dirigeants chez Oric Pharmaceuticals.
Pharmacie
Oric Pharmaceuticals a 1 867 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
- Frontier Medicines vient d'annoncer une levée de fonds de 80 millions de dollars. (publié le 27 février 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Oric Pharmaceuticals
- ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020 | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II | ORIC Pharmaceuticals, Inc.
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Oric Pharmaceuticals
- Oric Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Oric Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Jacob Chacko 
Appelez Oric Pharmaceuticals au +1 650...
